Valuation: Incyte Corporation

Market Cap 24.23B 21.06B 19.6B 18B 33.99B 2,313B 34.51B 231B 90.68B 1,151B 90.98B 88.99B 3,861B P/E 2026 *
55x
P/E 2027 * 16.5x
Enterprise Value 19.98B 17.37B 16.16B 14.84B 28.03B 1,907B 28.46B 191B 74.78B 949B 75.03B 73.38B 3,184B EV / Sales 2026 *
3.36x
EV / Sales 2027 * 2.96x
Free-Float
98.13%
Yield 2026 *
-
Yield 2027 * -
1 day-2.82%
1 week+1.57%
1 month+5.43%
3 months+25.45%
6 months+19.44%
Current year+21.01%
1 week 117.25
Extreme 117.25
132.6
1 month 110.56
Extreme 110.56
132.6
Current year 89.25
Extreme 89.25
132.6
1 year 75.48
Extreme 75.48
132.6
3 years 50.27
Extreme 50.27
132.6
5 years 50.27
Extreme 50.27
132.6
10 years 50.27
Extreme 50.27
153.15
Manager TitleAgeSince
Chief Executive Officer 58 26/06/2025
Director of Finance/CFO 57 04/05/2026
President 62 05/06/2023
Director TitleAgeSince
Chairman 59 26/06/2025
Director/Board Member 72 20/01/2015
Director/Board Member 64 20/01/2015
Date Insider Type Main position Quantity % Market Cap.
23/7/26 Free

Chief Technology Officer

15,425 0.0077%
23/7/26 Free

EVP, Head of Incyte Intl

28,921 0.0145%
16/7/26 Free

EVP & Chief Scientific Officer

46,244 0.0231%
Change 5-day change 1-year change 3-year change Capi.($)
-2.82%+1.57%+59.59%+87.57% 24.23B
+3.29%+16.25%+39.81%+2.79% 76.15B
-2.75%+48.50%+48.50%+48.50% 47.83B
+2.72%-9.39%+17.04%+176.83% 48.89B
-3.81%+7.74%-54.57%-54.17% 41.37B
-2.40%+0.38%+58.55%-24.89% 29.99B
-5.35%+1.39%+85.45%-53.41% 21.75B
-1.59%-3.61%-11.53%+150.58% 19.25B
-0.42%+2.89%+74.55%+128.45% 17.14B
-2.50%-4.68%+69.43%+128.76% 15.66B
Average -1.94%+0.87%+38.68%+59.10% 34.22B
Weighted average by Cap. -1.54%+2.63%+32.51%+47.52%

Financials

2026 *2027 *
Net sales 5.94B 5.17B 4.81B 4.41B 8.34B 567B 8.47B 56.68B 22.24B 282B 22.32B 21.83B 947B 6.22B 5.41B 5.03B 4.62B 8.73B 594B 8.86B 59.35B 23.29B 296B 23.37B 22.86B 992B
Net income 452M 393M 366M 336M 634M 43.15B 644M 4.31B 1.69B 21.48B 1.7B 1.66B 72.03B 1.48B 1.29B 1.2B 1.1B 2.08B 141B 2.11B 14.13B 5.54B 70.39B 5.56B 5.44B 236B
Net Debt -4.25B -3.69B -3.44B -3.16B -5.96B -406B -6.05B -40.53B -15.91B -202B -15.96B -15.61B -677B -5.81B -5.05B -4.7B -4.32B -8.15B -555B -8.28B -55.43B -21.76B -276B -21.83B -21.35B -926B
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
31/07/26 USD 119.52 -2.82% 1,830,263
30/07/26 USD 122.99 -3.23% 2,628,292
29/07/26 USD 127.10 -2.18% 2,917,698
28/07/26 USD 129.93 +9.30% 5,921,515
27/07/26 USD 118.87 +1.02% 2,729,176
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
119.52USD
Average target price
122.96USD
Spread / Average Target
+2.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INCY Stock